Rheonova participated in the Lung Invitro Event 2022 at the Hyatt Regency, Nice. LIVe2022 intends to be a unique exchange platform for scientists interested in in vitro respiratory researches, stakeholders from academia, pharma, biotech,...
Rheonova was present at the Congrès de Pneumologie de Langue Française 2022 in Lille where we presented our latest work on bronchial mucus heterogeinity: micro- and macro-rheology study Abstract In lung muco-obstructive diseases, such as cystic fibrosis, chronic...
Rheonova was present at the ECFS basic science 2022 at Albufeira. Our PhD student Lydia ESTEBAN ENJUTO presented her work on cystic fibrosis sputum handling for rheology. Muco-obstructive diseases, including cystic fibrosis, COPD or severe asthma feature an alteration...
Rheonova wishes you happy new year 2022!this past year have been rich, challenging and exciting, here is a small preview!
Rheonova is supported by the Auvergne Rhône-Alpes region to ensure compliance with the new European regulation for CE marking of our medical device Rheomuco and the associated quality management system. The region, in collaboration with the Agency, Lyonbiopole and...
We are happy to announce that Rheonova, in collaboration with Cedrat Technologies and the laboratories TIMA and LRP, have been granted the regional PSPC for the project MucoPiezoRheo. This project aims to develop a medical device for personalized diagnosis and...
Rheonova is proud to announce that the RheoCare project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 889360. The aim is to implement an automated sample manipulation device on the Rheomuco....
North American Cystic Fibrosis Conference will stand in few days. Rheonova team would be glad to meet you there and present its Poster n°529 “RHEOLOGICAL SIGNATURE OF INDUCTION ON CF SPUTUM: SPONTANEOUS VERSUS HYPERTONIC SALINE VERSUS RHDNASE”
Following Rheomuco's first sales to research laboratories in Europe, Rheonova wishes to boost its commercial activity. And to bring Rheomuco to the patient's bedside, 2 new clinical trials are underway. The first at Cochin Hospital for patients with cystic fibrosis...